Tweet

Divya Tej Sowpati

18 Oct, 3 tweets, 2 min read

@CSIR_IND

Interesting story. To further add to this, out of ~4k Indian SARS-CoV-2 genomes currently in the public domain (GISAID/SRA), more than half were submitted by @CSIR_IND labs, of samples from across India.

https://twitter.com/IndiaToday/status/1317671907940913152

@IGIBSocial

Our recent work in collab with @IGIBSocial shows that with time, SARS-CoV-2 genomes have near uniformity across India, and are similar to those present globally, and hence can expect equal efficacy of vaccines/drugs.
See the peer-reviewed version here:
doi.org/10.1093/ofid/o…

An updated list of all catalogued genomes and respective variants are maintained at clingen.igib.res.in/indicov/ and data.ccmb.res.in/gear19/

• • •

Missing some Tweet in this thread? You can try to force a refresh

This Thread may be Removed Anytime!

Twitter may remove this content at anytime! Save it as PDF for later use!

More from @TejSowpati

Divya Tej Sowpati

@TejSowpati

19 Sep

@OxUniPress

Our updated analysis on #SARSCoV2 clades in India, now peer-reviewed and published in OFID by @OxUniPress. In collaboration with @vinodscaria @IGIBSocial. Congratulations to the entire team.
doi.org/10.1093/ofid/o…
#Genomics #IndiaFightsCOVID19

I’ve never done one of these before, but I’m gonna make a thread of tweets explaining the key findings, and more importantly what our paper doesn’t show. 1/n

First and foremost, there is no conclusive evidence at present that any clade of SARS-CoV-2 is associated with increased mortality or severity of the disease. 2/n

Read 11 tweets

Share this page!

Divya Tej Sowpati

Try unrolling a thread yourself!

More from @TejSowpati

Divya Tej Sowpati

Did Thread Reader help you today?

Like this author's thread?